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Kidney Int 2012(Suppl 2):181-5. and four (80%) patients had a resistant disease with two (40%) of them receiving renal replacement therapy.
Al-Shamari et al. [2] described three HIV-negative patients with coexistent CG and MN who progressed to advanced chronic kidney disease despite immunosuppressive therapy. Although well known to be associated with autoimmune diseases, [1] primary MN is not commonly described with CG and the pathogenesis is uncertain. A possibility of viral infection causing both podocyte injury (CG) and increased expression of viral antigens on the podocyte foot process leading to immune complex deposition (MN) was also put forward. [2] To conclude, we observed 80% of patients to be resistant to therapy among five non-HIV-infected patients with coexistent MN and CG. The association of CG in patients with primary MN may act as a poor prognostic factor for response to standard therapy. Larger prospective multicentric studies shall provide a better understanding of this association.
Sir, Edema, the chief clinical manifestation of nephrotic syndrome, often can be severe, more so in patients with steroid-resistant nephrotic syndrome (SRNS). Severe edema requires prolonged therapy with furosemide, which may be associated with adverse effects. While patients with hypovolemia benefit from administration of intravenous (IV) albumin with or without furosemide, the former is expensive and carries the risk of pulmonary edema in patients with oligouria. Tolvaptan, an antagonist of the arginine vasopressin receptor, increases free water excrection and diuresis. [1] Shimizu et al. first reported use of tolvaptan in an 8 year-old girl with nephrotic syndrome and refractory edema. [2] We report our experience with the combination of oral tolvaptan and IV furosemide in patients with nephrotic syndrome in whom the edema was refractory to IV furosemide alone.
We studied 10 patients (6 boys) with a median age of 7 (6-14) years, who received therapy with oral tolvaptan (0.5-1 mg/kg/day) and IV furosemide (3-4 mg/kg/day) for 48 h. Combination therapy was associated with significant increase in urine volume, from 1.2 (0.9-2.7) mL/kg/h at baseline to 2.4 (2.0-3.3) mL/kg/h at 48 h of therapy. There was a small but significant reduction in body weight from baseline 20.5 to 19.9 kg after 48 h. Serum sodium increased significantly from 133 mEq/L at baseline to 140.5 mEq/L after combination therapy. Three patient showed hypernatremia (serum sodium >145 mEq/L). Table 1 shows other parameters before and after combination therapy. None of the patients developed clinical evidence of hypovolemia during the study.
Our study demonstrates that combination therapy with oral tolvaptan and IV furosemide increases the urine output, without affecting renal function. Hypoalbuminemia in nephrotic syndrome results in impaired furosemide delivery to the tubular lumen at its site of action in thick ascending loop of Henle contributing to furosemide resistance. Since tolvaptan acts on the basolateral side of collecting duct and does not require secretion into the tubular lumen, its aquaretic action is not affected by the blood level of albumin. The therapeutic efficacy of vasopressin receptor antagonist is well demonstrated in the management of fluid retention in congestive heart failure and cirrhosis. [3] Recently, in a case series of 14 patients with nephrotic proteinuria secondary to diabetic nephropathy, improvement in furosemide refractory edema with tolvaptan therapy was described. [4] Finding from this study shows that coadministration of tolvaptan and furosemide is effective in increasing urine output in patients with furosemide resistant edema due to nephrotic syndrome. While therapy is safe, careful monitoring of serum sodium is essential. Prospective controlled studies are required to examine whether tolvaptan is an effective and safe oral therapy for management of edema in nephrotic syndrome.
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Discordance between Flow-Cytometry Crossmatch and Single Antigen Bead (SAB) Assay: An Uncommon Finding and its Resolution
Sir, An acute or hyper-acute rejection in any solid organ transplant is due to the presence of preformed anti-HLA antibodies. [1] These antibodies can be identified with cell-based assays; Complement-dependent Lympho-Cytotoxicity Crossmatch (CDCXM) and Flow Cytometry crossmatch (FCXM) and bead-based assays; Panel Reacting Antibodies (PRA) and Single Antigen Bead (SAB). [2] Using cell-based and bead-based assays in an algorithmic manner combines relative merits of each assay to our advantage and allows better interpretation of results. Routinely, in a pre-renal transplant work-up, commonest scenarios are where cell-based crossmatch and SAB are concordant, either negative or positive. We present a case that belongs to a third scenario, an unusual presentation, where CDCXM and FCXM were negative; SAB was positive and virtual crossmatch revealed Donor Specific Antibody (DSA).
A 25-year-old male patient suffering from end-stage renal disease was referred to our laboratory by the nephrologist for pre-transplant workup with his wife as prospective donor. As per the institutional protocol, low resolution HLA typing for class I (A and B) and class II (DR) antigens {polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP)} was performed for assessing relationship as a pre-requisite according to The Human Organ Transplant Act, India, 1994 and its amendments. [3] Anti-HLA antibody detection was negative by CDCXM and FCXM. CDCXM was performed using the standard National Institute of Health (NIH) technique and FCXM was performed for T-cell and B-cell on BD FACSVerse™ Flow cytometer (San Jose, CA, USA). Since the patient had history of blood transfusion, PRA was performed using Flow PRA Class I & II Screening Test kit (One Lambda, Inc., CA, USA) and it was found positive. As this scenario presented a discrepancy between cell-based and bead-based methods, repeat testing were done to rule out any technical errors. However, results remained the same.
Decision was taken to perform SAB assay (LIFECODES LSA™ Kit, Immucor Transplant Diagnostics Inc., USA) on Luminex platform. SAB assay was positive for class I antibodies and negative for class II antibodies. Antibodies were identified against HLA-A*24:03 (MFI-11531) and HLA-A*24:02 (MFI-5252). Low resolution typing identified donor HLA-A allele as A*24 only. Therefore, high resolution typing for donor HLA-A locus was also done to identify complete antigen. High resolution typing revealed HLA-A*24:03 in donor and confirmed the presence of DSA.
To further understand and resolve this uncommon discrepancy between cell-based crossmatch and SAB, literature was reviewed. [4] Of all the possible mentioned reasons for such discordance, performing tests to negate pro-zone and post-zone phenomenon was undertaken and FCXM was repeated with dilutions of recipient's serum and donor's cells (dilutions 1:2 to 1:8). FCXM was found to be positive for T cells (median channel shift was 59; cut-off ≥26) and negative for B cells (median channel shift was 98; cut-off ≥110) with donor cells in 1:2 dilutions [ Table 1 and Figure 1 ]. This positive result for T-cell FCXM corroborated with SAB results and resolved the discrepancy.
All tests, CDCXM, FCXM, PRA, and SAB, are used to detect the presence of donor-specific anti-HLA antibodies (DSA) in the recipient and in most of the cases, results of all tests are in concordance. However, rarely there can be discordance. Literature review identified following reasons for discordance: Pro-zone/Post-zone effect, stability of antigens, antibody against denatured antigens v/s native antigen and allelic expression on the donor cell surface.
In the present case, post-zone phenomenon was responsible for the discordance between results of cell-based and bead-based assays. Excess of antigen inhibits lattice formation and subsequent agglutination between antigen-antibody may not occur, which can give
